Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Merit Hanna
Observed names:
M. Hanna,
Merit Z Hanna
Institutions:
North Shore Hospital,
Waitemata District Health Board
Observed institutions:
North Shore Hospital,
Waitemata District Health Board,
Health New Zealand
OpenAlex ID:
A5112933431
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
2024
·
Mazyar Shadman
, Talha Munir
, et al.
·
Journal of Clinical Oncology
·
88
P639: Zanubrutinib (zanu) Vs Bendamustine + Rituximab (br) in Patients (pts) With Treatment-naïve Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (cll/sll): Extended Follow-up of the Sequoia Study
2023
·
Talha Munir
, Mazyar Shadman
, et al.
·
HemaSphere
·
18
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY
2023
·
M. Shadman
, T. Munir
, et al.
·
Hematological Oncology
·
15
PDF
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
2022
·
Harinder Gill
, Francesca Palandri
, et al.
·
Blood
·
14
Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations
2023
·
Joachim R. Goethert
, Harinder Gill
, et al.
·
Blood
·
13
P1033: a Phase 2 Study of the Lsd1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (et)
2022
·
F. Palandri
, D. M. Ross
, et al.
·
HemaSphere
·
10
Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia
2026
·
Harinder Gill
, Francesca Palandri
, et al.
·
Blood Advances
·
8
PDF
Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal
2021
·
Louisa Stone
, Eileen Merriman
, et al.
·
Thrombosis and Haemostasis
·
8
A Machine Learning PROGRAM to Identify COVID-19 and Other Diseases From Hematology Data
2021
·
Patrick A Gladding
, Zina Ayar
, et al.
·
Future Science OA
·
8
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
2025
·
Meletios A Dimopoulos
, Meral Beksac
, et al.
·
The Lancet Haematology
·
7
The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients: a single-center experience
2022
·
Rory Bennett
, Henry Chan
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
3
Distinctive features of polycythaemia vera in New Zealand Polynesians.
2018
·
Merit Z Hanna
, Maggie L Kalev-Zylinska
, et al.
·
PubMed
·
3
Idiopathic factor V inhibitor in a patient starting haemodialysis
2022
·
Luke J. Sutherland
, Sarah Tan
, et al.
·
Internal Medicine Journal
·
2
Fixed‐dose three‐factor prothrombin complex concentrates is safe and effective in warfarin reversal
2020
·
Kirsty Marshall
, Eileen Merriman
, et al.
·
Internal Medicine Journal
·
2
Daratumumab-induced pancytopenia: collateral damage from the silver bullet
2020
·
Brian Grainger
, Merit Hanna
, et al.
·
Pathology
·
2
PDF
Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)
2018
·
Lauren Child
, Henry Chan
, et al.
·
Blood
·
2
Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma
2012
·
David Simpson
, James Liang
, et al.
·
Blood
·
2
Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study
2025
·
David Ross
, Andrew Wilson
, et al.
·
Blood
·
1
PDF
P675: Imatinib Therapy in Previously Untreated Chronic Myeloid Leukaemia Patients Who Achieve Mmr After 12 Months Therapy With Dasatinib: a Strategy to Avoid Long Term Off Target Toxicity
2023
·
Lucy Pemberton
, Katrina Sharples
, et al.
·
HemaSphere
·
1
Intrasinusoidal proerythroblast infiltration in therapy related myeloid neoplasm
2023
·
Jian Li
, Merit Hanna
·
Blood Research
·
1
PDF
Is initial treatment with dasatinib for newly diagnosed chronic Phase chronic myeloid leukemia, followed by switching to imatinib for those that achieve MR3.0 at 12 months, an effective strategy? Results of the Phase 2 kinase inhibition with sprycel startup study
2025
·
Peter Browett
, Zhenqiang Wu
, et al.
·
Blood
Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.
2025
·
Marcelo Pitombeira de Lacerda
, Meletios Athanasios Dimopoulos
, et al.
·
Journal of Clinical Oncology
Highly atypical lymphoid proliferation after COVID-19 vaccine, with spontaneous regression
2024
·
Jian Li
, Anna Ruskova
, et al.
·
Journal of Hematopathology
PDF
Conservative Management of Hemochromatosis without Long-Term Maintenance Venesections in Patients with Moderate Iron Burden
2020
·
Jenny Sumin Yoon
, Ross Alistair Henderson
, et al.
·
Blood
Pb2138 Light Chain (al) Amyloidosis: a Single Centre Experience and the Effectiveness of Bortezomib Based Therapy as First Line Therapy
2019
·
H. Ngu
, D. Simpson
, et al.
·
HemaSphere
Show more works
View as search
Works count:
26
Citation count:
208
H-index:
8
I10-index:
6
Year
Topic
Type
